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The design of novel anti-HIV vaccination and gene ther-
apy strategies will be presented, including pilot experi-
ments in animal models. Our gene therapy approach uses
the RNA interference (RNAi) machinery to make human
cells resistant to HIV-1. The problem of viral escape and
the control of viral escape by means of a combination-
RNAi therapy will be discussed. A humanized mouse
model has been set up as pre-clinical test system to
address the safety and efficacy of lentiviral vector-deliv-
ered RNAi cassettes. Our vaccination approach deals with
the novel concept of a conditional-live virus that can be
turned on and off at will. Live-attenuated virus confers the
most potent protection against wild-type virus challenge
in the SIV/macaque vaccination model. However, such a
vaccine is not pursued because of safety reasons as the vac-
cine virus persists and may evolve into a pathogenic vari-
ant. We therefore designed an SIVmac239Δnef variant
that is dependent on doxycycline for replication by replac-
ing the natural Tat/TAR transcription mechanism by the
Tet-system for inducible gene expression. Replication of
this virus can be switched off after vaccination, which will
prevent evolution. The first rhesus macaque test yielded a
marked vaccine effect. This new conditional-live virus will
be a useful tool to identify the correlates of protection by
this vaccine strategy.
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